Patent application number | Description | Published |
20080227825 | Formulation - This invention relates to a formulation comprising a dipeptidylpeptidase IV (DPP-IV) inhibitor preferably vildagliptin and metformin, to tablets comprising such formulations and to processes for the preparation thereof. | 09-18-2008 |
20090148522 | HEATED ROLLER COMPACTION PROCESS FOR MAKING PHARMACEUTICAL COMPOSITIONS - A process for using a heated roller compactor to prepare melt granulated composition of a therapeutic compound, especially a poorly compressible and/or moisture sensitive therapeutic compound, with a granulation excipient. | 06-11-2009 |
20100021539 | Modified Release 1-[(3-Hydroxy-Adamant-1-Ylamino)-Acetyl]-Pyrrolidine-2(S)-Carbonitrile Formulation - The subject invention provides a pharmaceutical tablet formulation comprising per unit dosage form e.g. per tablet the following ingredients:
| 01-28-2010 |
20100179182 | PHARMACEUTICAL FORMULATION - The present invention provides processes for making and forms of solid dispersions of pharmaceutical active ingredients. | 07-15-2010 |
20100209480 | GALENICAL FORMULATIONS OF ORGANIC COMPOUNDS - The present invention relates to a pharmaceutical oral fixed dose combination comprising
| 08-19-2010 |
20110037185 | CONTINUOUS PROCESS FOR MAKING PHARMACEUTICAL COMPOSITIONS - A process for manufacturing solid oral dosage forms in an equipment train that comprises multiple pieces of apparatus designed for unit operations, such as blending, extruding, cooling, milling and finishing. The equipment in the equipment train allow for the transfer of raw materials and intermediate-processed materials from one apparatus to the next using transfer means, for example, gravity, vacuum, belts, and the like. | 02-17-2011 |
20110045062 | FORMULATION - This invention relates to a formulation comprising a dipeptidylpeptidase IV (DPP-IV) inhibitor preferably vildagliptin and metformin, to tablets comprising such formulations and to processes for the preparation thereof. | 02-24-2011 |
20110086096 | MODIFIED RELEASE 1- [ (3-HYDROXY-ADAMANT-1-YLAMINO)-ACETYL] -PYRROLIDINE-2 (S) -CARBONITRILE FORMULATION - The subject invention provides a pharmaceutical tablet formulation comprising per unit dosage form e.g. per tablet the following ingredients:
| 04-14-2011 |
20110177166 | Galenical Formulation Comprising Aliskiren and Process for its Preparation by Melt Extrusion Granulation - The present invention relates to galenic formulations wherein the active ingredient aliskiren, preferably, a hemi-fumarate salt thereof, alone or in combination with another active ingredient, is melt-granulated and is present in an amount of more than 20% by weight based on the total weight of the oral dosage form, as well as a process of preparing said solid oral dosage form. | 07-21-2011 |
20120077879 | Process for making compositions with poorly compressible therapeutic compounds - A process for preparing solid dosage forms that contain poorly compressible therapeutic compound. The process, for example, provides for the inventive use of an extruder, especially a twin screw extruder, to melt granulate a therapeutic compound(s) with a granulation excipient. | 03-29-2012 |
20120294939 | DIRECT COMPRESSION FORMULATION AND PROCESS - Dipeptidylpeptidase IV inhibitor (herein referred to as DPP-IV) that may be 98.5-100% pure is a high-dose drug capable of direct compressed with specific excipients into sold form dosage forms, such as tablets and capsules having desired, hardness, disintegrating ability and acceptable dissolution characteristics. DPP-IV is not inherently compressible and thus present formulation problems. Excipients used in the formulation enhance the flow and compaction properties of the drug and tableting mix. Optimal flow contributes to uniform die fill and weight control. The binder used ensures sufficient cohesive properties that allow DPP-IV to be compressed using the direct compression method. The tablets produced provide an acceptable in vitro dissolution profile. | 11-22-2012 |
20130052239 | Formulation - This invention relates to a formulation comprising a dipeptidylpeptidase IV (DPP-IV) inhibitor preferably vildagliptin and metformin, to tablets comprising such formulations and to processes for the preparation thereof. | 02-28-2013 |
20140205663 | Direct Compression Formulation and Process - Dipeptidylpeptidase IV inhibitor (herein referred to as DPP-IV) that may be 98.5-100% pure is a high-dose drug capable of direct compressed with specific excipients into sold form dosage forms, such as tablets and capsules having desired, hardness, disintegrating ability and acceptable dissolution characteristics. DPP-IV is not inherently compressible and thus present formulation problems. Excipients used in the formulation enhance the flow and compaction properties of the drug and tableting mix. Optimal flow contributes to uniform die fill and weight control. The binder used ensures sufficient cohesive properties that allow DPP-IV to be compressed using the direct compression method. The tablets produced provide an acceptable in vitro dissolution profile. | 07-24-2014 |
20140287040 | Formulation - This invention relates to a formulation comprising a dipeptidylpeptidase IV (DPP-IV) inhibitor preferably vildagliptin and metformin, to tablets comprising such formulations and to processes for the preparation thereof. | 09-25-2014 |